4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.63 Average PT from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $30.63.

Several analysts have weighed in on the company. Morgan Stanley cut their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th. Leerink Partners cut their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Bank of America cut their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Finally, BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $40.00 to $15.00 in a research report on Monday, January 13th.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $3.79 on Monday. 4D Molecular Therapeutics has a 1 year low of $3.66 and a 1 year high of $36.25. The company has a market cap of $175.48 million, a PE ratio of -1.33 and a beta of 2.83. The stock’s 50-day moving average is $4.77 and its 200 day moving average is $7.60.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FDMT. KLP Kapitalforvaltning AS bought a new position in 4D Molecular Therapeutics in the 4th quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. bought a new position in 4D Molecular Therapeutics in the 4th quarter valued at approximately $50,000. PNC Financial Services Group Inc. lifted its position in 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after acquiring an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after acquiring an additional 9,737 shares in the last quarter. Finally, Velan Capital Investment Management LP bought a new position in 4D Molecular Therapeutics in the 4th quarter valued at approximately $56,000. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.